OpenAI acquires Orchestra Bio to push AI agents into drug development

OpenAI has acquired Orchestra Bio, a four-year-old AI biotech software startup, the company announced on Tuesday, 20 October 2026.

Orchestra builds AI agents that help biotechnology and pharmaceutical teams manage the minutiae of drug development operations, from tracking finances to resolving scheduling issues with clinical trials. Its software can, for example, identify which studies would be affected if a manufacturing problem held up medicine needed for a trial, and suggest possible adjustments.

Financial terms of the deal were not disclosed. The startup had reportedly raised around $20 million as of 2025 from backers including Andreessen Horowitz and 8VC.

OpenAI says Orchestra’s team and technology will join Rosalind, its AI models and tools for life-sciences research, alongside the Rosalind Workbench harness, which aims to help researchers plan experiments and analyse results. The company says Rosalind customers already include Moderna and Novo Nordisk.

The acquisition targets a long-standing bottleneck in the industry: OpenAI says developing a new medicine typically takes 10 to 15 years from identifying a promising biological target to securing US regulatory approval.

Axios first reported the deal, according to TipRanks.

Sources

• https://techcrunch.com/2026/10/20/openai-acquires-startup-orchestra-bio%e2%81%a0-to-beef-up-its-biotech-business/ (TechCrunch, 20 Oct 2026)
• https://www.tipranks.com/news/ma-news-openai-acquires-orchestra-bio-to-speed-up-drug-development-with-ai (TipRanks, 20 Oct 2026)
• https://dealroom.co/news/164436-openai-buys-orchestra-bio-to-push-ai-agents-into-drug-development/ (DealRoom News, 20 Oct 2026)
• https://interestingengineering.com/ai-robotics/openai-acquires-orchestra-bio-drug-development (Interesting Engineering, 20 Oct 2026)